Coherent Unveils 400 mW CW Lasers and 2D VCSEL/PD Arrays for AI Data Centers

COHR
September 26, 2025
Coherent Corp. announced today the sampling of a new 400 mW continuous‑wave laser operating at 1311 nm. The laser delivers stable output power above 400 mW at 55 °C, a spectral linewidth below 200 kHz, and relative intensity noise below –145 dB/Hz. Built on the company’s Buried‑Heterostructure Distributed‑Feedback platform, the device is engineered for co‑packaged optics and silicon photonics applications. In a separate announcement, Coherent demonstrated a next‑generation 2D VCSEL and photodiode array optimized for short‑reach AI data‑center interconnects. The array operates at 850 nm, supports 32 × 50 G NRZ channels, and is designed to replace copper links in high‑density AI workloads. The high‑density architecture enables power‑efficient, low‑latency links that are critical for scaling AI/ML workloads in hyperscale data centers. Both product launches reinforce Coherent’s strategy to dominate the AI data‑center market. The 400 mW CW laser’s low noise and high power make it attractive for co‑packaged optics, while the 2D VCSEL/PD array’s compact, high‑density design addresses the growing demand for short‑reach optical interconnects. Together, they expand the company’s portfolio in high‑performance photonics and position Coherent to capture new revenue streams in the rapidly expanding AI and data‑center segments. Engineering samples of the 400 mW laser are now available to select customers, and the 2D VCSEL/PD array has been demonstrated at industry events. These releases signal Coherent’s continued investment in cutting‑edge photonic technologies and its commitment to delivering solutions that meet the stringent performance requirements of next‑generation data‑center networks. The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.